Special drug use survey of DARZQURO Combination Subcutaneous Injection (Multiple Myeloma)

Special drug use survey of DARZQURO Combination Subcutaneous Injection (Multiple Myeloma) - DRQ1L

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044074

Enrollment

200

Registered

2021-06-01

Start date

2021-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have never treated with Darzalex IV and treated with this drug for the first time according to the indication. Patients who understand the contents of this survey and consent to participate in this survey.

Exclusion criteria

Exclusion criteria: Patients with a history of the use of Daratumumab.

Design outcomes

Primary

Measure	Time frame
Safety(Adverse Drug Reaction)	—

Countries

Japan

Contacts

Public ContactHIROKAZU SHIRAI

Janssen Pharmaceutical K.K. Safety Risk Management Dept.

hshirai3@ITS.JNJ.com03-4411-5136

Outcome results